Cresco Labs Inc. (OTCMKTS:CRLBF) Given Average Rating of “Moderate Buy” by Analysts

Shares of Cresco Labs Inc. (OTCMKTS:CRLBF) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $2.50.

A number of equities research analysts recently commented on CRLBF shares. Roth Capital upgraded Cresco Labs to a “strong-buy” rating in a research report on Sunday, November 10th. Cormark cut Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th. Finally, Atb Cap Markets lowered Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th.

Cresco Labs Price Performance

Shares of Cresco Labs stock opened at $0.93 on Friday. The stock has a market capitalization of $453.97 million, a price-to-earnings ratio of -4.65 and a beta of 1.79. The firm’s 50-day moving average price is $0.97 and its two-hundred day moving average price is $1.37. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. Cresco Labs has a 1-year low of $0.78 and a 1-year high of $2.65.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.